Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema

NCT05217680 is registered in ClinicalTrials.gov with Laboratorios Sophia S.A de C.V. as lead sponsor.

NCT NCT05217680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05217680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema
Lead sponsor
Laboratorios Sophia S.A de C.V.
Phase
Phase 3
Overall status
Completed
Start date
May 24, 2021
Completion date
November 25, 2025
Enrollment
509 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema